Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope.
作者信息
Argnani Lisa, Casadei Beatrice, Zinzani Pier Luigi
机构信息
Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
出版信息
Blood Cancer J. 2025 Mar 7;15(1):33. doi: 10.1038/s41408-025-01246-4.
Abstract
摘要
相似文献
1
Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope.嵌合抗原受体T细胞疗法意向性分析中的不同定义取决于研究范围。
Blood Cancer J. 2025 Mar 7;15(1):33. doi: 10.1038/s41408-025-01246-4.
2
Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.意向治疗与 B 细胞成熟抗原和 CD19 嵌合抗原受体试验的改良意向治疗分析：系统评价和荟萃分析。
Eur J Cancer. 2021 Oct;156:164-174. doi: 10.1016/j.ejca.2021.07.036. Epub 2021 Aug 26.
3
Defining 'Intention' in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy.在嵌合抗原受体T细胞疗法的意向性分析生存结果中定义“意向性”
Blood Cancer J. 2025 Feb 8;15(1):16. doi: 10.1038/s41408-025-01220-0.
4
Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report.细胞因子释放综合征和免疫效应细胞相关神经毒性综合征患者的嵌合抗原受体T细胞相关毒性管理，随后发生肠穿孔：一例报告
J Med Case Rep. 2025 Jan 20;19(1):27. doi: 10.1186/s13256-024-04905-5.
5
Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy-A Case Report.体外血液净化在嵌合抗原受体T细胞疗法后治疗严重难治性神经毒性中的新应用——一例报告
Crit Care Explor. 2021 Jun 29;3(7):e0472. doi: 10.1097/CCE.0000000000000472. eCollection 2021 Jul.
6
Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.血液系统恶性肿瘤嵌合抗原受体 T 细胞治疗的研究趋势和活跃研究领域的文献计量学分析。
Int J Clin Pharm. 2024 Feb;46(1):186-194. doi: 10.1007/s11096-023-01670-1. Epub 2023 Dec 12.
7
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.新型抗 CD19 嵌合抗原受体构建的 CD19 CAR T 在复发或难治性急性淋巴细胞白血病中的疗效和安全性。
J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8.
8
Global Manufacturing of CAR T Cell Therapy.嵌合抗原受体T细胞疗法的全球生产
Mol Ther Methods Clin Dev. 2016 Dec 31;4:92-101. doi: 10.1016/j.omtm.2016.12.006. eCollection 2017 Mar 17.
9
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.采用严格的事件定义，通过国家准入计划，评估接受 tisagenlecleucel 治疗的 r/r ALL 儿童和青少年的意向治疗结局。
Blood Cancer J. 2024 Apr 15;14(1):66. doi: 10.1038/s41408-024-01038-2.
10
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells.通过基因工程嵌合抗原受体T细胞靶向癌症干细胞
Front Genet. 2020 Apr 22;11:312. doi: 10.3389/fgene.2020.00312. eCollection 2020.
本文引用的文献
1
Defining 'Intention' in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy.在嵌合抗原受体T细胞疗法的意向性分析生存结果中定义“意向性”
Blood Cancer J. 2025 Feb 8;15(1):16. doi: 10.1038/s41408-025-01220-0.
2
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.嵌合抗原受体T细胞（CAR T）是一种药物还是一种治疗途径？复发难治性弥漫性大B细胞淋巴瘤中CAR-T细胞疗法真实世界研究的意向性分析与符合方案分析。
Blood Cancer J. 2024 Nov 7;14(1):197. doi: 10.1038/s41408-024-01183-8.
3
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.弥漫性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞（CAR T）治疗及时给药障碍的真实世界分析。
Transplant Cell Ther. 2024 Nov;30(11):1082.e1-1082.e10. doi: 10.1016/j.jtct.2024.09.007. Epub 2024 Sep 11.
4
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity.真实环境下抗 CD19 CAR-T 细胞通路治疗大 B 细胞淋巴瘤的经济学评价：意大利枢纽中心开展活动的头三年经验。
Ann Hematol. 2024 Jul;103(7):2499-2509. doi: 10.1007/s00277-024-05766-0. Epub 2024 May 2.
Zotero 插件